Psych Editorial
  • Home
  • Contact

Meet the Pfizer Executive Leadership Team: John Young

Meet the Pfizer Executive Leadership Team: John Young 

John Young is President and General Manager of Pfizer’s Primary Care Business Unit and a member of Pfizer’s Executive Leadership Team. Prior to his appointment he was the Primary Care Business Unit’s Regional President for Europe and Canada, a position he held since 2009. John has deep experience in the primary care setting, its complex and evolving customer landscape, and the development of evolved customer facing channels and capabilities.

John began his 25-year career with Pfizer in 1987 as a sales representative in his native Scotland. He progressed through a number of sales and marketing management roles and was UK Sales Director from 1998 and UK Marketing Director from 2000. In 2004 he was appointed Country Manager for Australia/New Zealand, and returned to the UK as Country Manager in 2007, prior to assuming his previous role leading the Primary Care Business Unit in Europe/Canada.

During his career John has also held leadership roles within local and regional industry groups, including the Association of the British Pharmaceutical Industry (ABPI) and Medicines Australia, where as Chair he led negotiations with the government to reform the country’s Pharmaceutical Benefits Scheme (PBS). Additionally, John is active in community work to serve vulnerable populations.

John holds a Bachelor of Science degree in Biology from Glasgow University and an MBA from Strathclyde Graduate Business School.

Source: Pfizer Press Releases – Meet Our Executives

Related Posts

Takeda Pharmaceuticals

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero

News & Views

  • Now Accepting Content
  • Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder
  • Introducing the New Kid on the Block to Treat Depression: “Brintellix”.
  • Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh
  • Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero
Psych Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!